$CVS

CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now?

CVS Health (CVS) and Alignment Healthcare (ALHC) are major players in the growing Medicare Advantage market. CVS's Aetna segment saw improved margins and strong CMS ratings, while ALHC expanded membership and improved efficiency. CVS stock rose 9.9% over the past year, while ALHC fell 50.8%. CVS has a lower forward P/E (10.41) compared to ALHC (25.43), and its 2026 EPS estimates increased 1.8% in the past 60 days, unlike ALHC's 17.6% drop.

Original reporting
Published Oct 14, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 1:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CVS vs. ALHC: Which Medicare Advantage Stock Is the Better Pick Now? — source image
Decision brief

The 30-second read

$CVSBullishLow
01

Why it matters

Provides a side‑by‑side assessment but does not introduce new earnings, guidance, or contract data.

02

Market read

Useful for investors weighing MA stocks, but limited trading relevance due to lack of fresh material.

03

What to watch

Potential regulatory changes to Medicare Advantage reimbursement and the impact of AI‑driven cost management at CVS are not quantified.

Relevance 4/10Novelty 3/10Timing: none

Background

The article is a Zacks comparison of two Medicare Advantage stocks, focusing on recent performance, margins, and valuation.

Company-level read

Ticker impact

$CVSBullishMedium confidence
Context

The article compares CVS Health's Medicare Advantage performance and notes its 9.9% share price gain over the past year.

Expected impact

likely modest upside as investors favor the margin turnaround narrative

Evidence & confidence

Improved Aetna margins and lower forward P/E suggest relative attractiveness, but no new catalyst is disclosed.

$ALHCBearishMedium confidence
Context

The piece details Alignment Healthcare's 50.8% share price decline and recent membership growth, noting a lower forward P/E.

Expected impact

likely further downside as investors remain wary of higher costs and slower earnings growth

Evidence & confidence

No fresh catalyst; the article merely recaps recent performance and valuation metrics.

Market effects

Highlights the broader Medicare Advantage sector growth, but offers no new sector‑wide catalyst.

U.S. health‑insurance market perception may shift slightly toward lower‑valued MA providers.

Limited to U.S. health‑care investors; no global macro impact.

Counterpoint

Alignment Healthcare's higher forward P/E could be justified if its membership expansion accelerates earnings faster than expected.

Key entities

  • CVS Health

    U.S. health‑care conglomerate with Aetna Medicare Advantage business.

  • Alignment Healthcare

    U.S. Medicare Advantage provider.

Related articles

$UNHMed

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.

$CVSLow

CVS Pharmacy, Inc. agreed to pay $315 million to resolve allegations of illegally filling opioid prescriptions and billing federal health programs

CVS Pharmacy, Inc. agreed to pay $315 million to resolve allegations of illegally filling opioid prescriptions and billing federal health programs. The settlement includes $189 million for False Claims Act violations and $126 million for Controlled Substances Act violations. CVS denies wrongdoing but agreed to implement stricter oversight and training programs.

$CVSMed

CVS Reaches Settlement With DOJ In Opioid Prescription Case

CVS Health Corp. will pay $315 million to resolve allegations of illegal opioid prescriptions and false claims to federal healthcare programs, according to a DOJ complaint. The settlement covers violations from 2013 to 2025 and includes additional safety measures for CVS. The case was initially filed by a whistleblower and involved unsafe prescribing practices, corporate negligence, and prioritizing profits over patient safety, per the DOJ.